Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKAN NASDAQ:BCTX NASDAQ:LNAI NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$27.00-27.4%$7.50$2.30▼$209.02$19.87M14.496.67 million shs395,213 shsBCTXBriacell Therap$4.19+2.2%$4.14$3.60▼$37.20$29.73M1.26154,035 shs79,064 shsLNAILunai Bioworks$0.33-0.9%$0.35$0.15▼$5.50$8.05M0.3410.13 million shs1.19 million shsPLRZPolyrizon$16.34+15.6%$13.22$2.88▼$664.05$26.47M-2.0458,889 shs153,662 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda0.00%-24.04%+1,097.75%+760.88%-54.64%BCTXBriacell Therap0.00%-1.91%-7.45%-1.91%-87.52%LNAILunai Bioworks0.00%+0.91%-6.72%-49.73%+33,299,900.00%PLRZPolyrizon0.00%-11.07%+25.13%+10.04%-98.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$27.00-27.4%$7.50$2.30▼$209.02$19.87M14.496.67 million shs395,213 shsBCTXBriacell Therap$4.19+2.2%$4.14$3.60▼$37.20$29.73M1.26154,035 shs79,064 shsLNAILunai Bioworks$0.33-0.9%$0.35$0.15▼$5.50$8.05M0.3410.13 million shs1.19 million shsPLRZPolyrizon$16.34+15.6%$13.22$2.88▼$664.05$26.47M-2.0458,889 shs153,662 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda0.00%-24.04%+1,097.75%+760.88%-54.64%BCTXBriacell Therap0.00%-1.91%-7.45%-1.91%-87.52%LNAILunai Bioworks0.00%+0.91%-6.72%-49.73%+33,299,900.00%PLRZPolyrizon0.00%-11.07%+25.13%+10.04%-98.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 1.00SellN/AN/ABCTXBriacell Therap 1.00SellN/AN/ALNAILunai Bioworks 1.00SellN/AN/APLRZPolyrizon 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LNAI, AKAN, BCTX, and PLRZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026BCTXBriacell Therap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026LNAILunai Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$840K17.04N/AN/A$210.79 per share0.13BCTXBriacell TherapN/AN/AN/AN/A$9.20 per shareN/ALNAILunai BioworksN/AN/AN/AN/A($1.24) per shareN/APLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$4.10MN/AN/AN/AN/AN/AN/AN/AN/ABCTXBriacell Therap-$26.31M-$23.33N/AN/AN/AN/A-173.08%-139.64%N/ALNAILunai Bioworks-$178.01M$0.056.60N/AN/AN/A-1,243.45%-360.31%N/APLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ALatest LNAI, AKAN, BCTX, and PLRZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2026Q4 2025PLRZPolyrizonN/A$2.81N/A-$2.81N/AN/A3/10/2026Q2 2026BCTXBriacell TherapN/A-$2.58N/A-$2.58N/AN/A2/17/2026Q2 2026LNAILunai BioworksN/A-$0.08N/A-$0.08N/AN/A2/14/2026Q4 2025PLRZPolyrizonN/A-$2.81N/A-$2.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/ALNAILunai BioworksN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/AN/AN/ABCTXBriacell TherapN/A10.1010.10LNAILunai BioworksN/A0.030.03PLRZPolyrizonN/A29.0329.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%BCTXBriacell Therap15.42%LNAILunai Bioworks71.41%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipAKANAkanda20.39%BCTXBriacell Therap0.74%LNAILunai Bioworks0.50%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda110530,000425,000Not OptionableBCTXBriacell Therap87.25 million7.20 millionNo DataLNAILunai Bioworks2024.19 million24.07 millionN/APLRZPolyrizonN/A1.87 millionN/AN/ALNAI, AKAN, BCTX, and PLRZ HeadlinesRecent News About These CompaniesPolyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery PlatformMay 4, 2026 | tipranks.comPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformMay 4, 2026 | globenewswire.comLipella Pharmaceuticals (NASDAQ:LIPO) & Polyrizon (NASDAQ:PLRZ) Head-To-Head AnalysisMay 2, 2026 | americanbankingnews.comPolyrizon (NASDAQ:PLRZ) Upgraded to Hold at Wall Street ZenMay 2, 2026 | americanbankingnews.comPolyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery TechnologyApril 27, 2026 | quiverquant.comQPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformApril 27, 2026 | globenewswire.comPLRZ Share News TodayApril 19, 2026 | uk.investing.comPolyrizon Raises $3.5 Million via Registered Direct Offering and Private PlacementApril 14, 2026 | theglobeandmail.comPolyrizon Ltd. Ordinary Shares (PLRZ) Institutional HoldingsApril 8, 2026 | nasdaq.comPolyrizon Ltd. Completes $3.5 Million Registered Direct Offering and Private PlacementApril 8, 2026 | quiverquant.comQPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsApril 8, 2026 | globenewswire.comPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementApril 7, 2026 | finance.yahoo.comPolyrizon Ltd. Ordinary Shares (PLRZ) Option ChainMarch 29, 2026 | nasdaq.comPolyrizon Ltd. Ordinary Shares (PLRZ) Insider ActivityMarch 28, 2026 | nasdaq.comPolyrizon Ltd.: Polyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | finanznachrichten.dePolyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | globenewswire.comPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025March 26, 2026 | markets.businessinsider.comPolyrizon Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025March 25, 2026 | quiverquant.comQPolyrizon Ltd. Signs Non-Binding MOU to Acquire Up to 20% Stake in Colugo Systems Ltd.March 24, 2026 | quiverquant.comQPolyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility ApplicationsMarch 24, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLNAI, AKAN, BCTX, and PLRZ Company DescriptionsAkanda NASDAQ:AKAN$27.00 -10.19 (-27.40%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$28.20 +1.20 (+4.46%) As of 05/8/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Briacell Therap NASDAQ:BCTX$4.19 +0.09 (+2.20%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.22 +0.03 (+0.62%) As of 05/8/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Lunai Bioworks NASDAQ:LNAI$0.33 0.00 (-0.90%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.31 -0.02 (-4.85%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Polyrizon NASDAQ:PLRZ$16.34 +2.20 (+15.56%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$16.61 +0.27 (+1.65%) As of 05/8/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
